SEC Form 4 · accession 0001104659-15-004406
EPIRUS Biopharmaceuticals, Inc. · EPRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jan 22, 2015
Accepted (ET)
Jan 26, 2015 · 1:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001135906
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3,F4 | Jan 22, 2015 | S | 14,130 | $6.2972 | D | 1,938,316 | D | |
| Common StockF2,F3,F4 | Jan 23, 2015 | S | 8,400 | $6.2737 | D | 1,929,916 | D | |
| Common StockF3,F5 | holding | — | — | — | 271,476 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.36, inclusive. The Reporting Person undertakes to provide to EPIRUS Biopharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range reported.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range reported.
- F3The securities reported herein reflect the 1-for-10 reverse stock split effected by the Issuer on July 16, 2014.
- F4Represents shares of common stock ("Common Stock") of the Issuer directly held by Montreux Equity Partners IV, L.P. John J. Savarese, M.D., Howard D. Palefsky and Daniel K. Turner III are the managers of Montreux Equity Management IV, LLC, which is the sole general partner of Montreux Equity Partners IV, L.P. By reason of these relationships, Montreux Equity Management IV, LLC, Dr. Savarese, Mr. Palefsky and Mr. Turner may be deemed to beneficially own the securities reported herein. Each of Montreux Equity Management IV, LLC, Dr. Savarese, Mr. Palefsky and Mr. Turner disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein.
- F5Represents shares of Common Stock of the Issuer directly held by Montreux Equity Partners V, L.P. Daniel K. Turner III is the sole manager of Montreux Equity Management V, LLC, which is the sole general partner of Montreux Equity Partners V, L.P. By reason of these relationships, Montreux Equity Management V, LLC and Mr. Turner may be deemed to beneficially own the securities reported herein. Each of Montreux Equity Management V, LLC and Mr. Turner disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein.